University of Calgary Studies Psychedelic Treatment for Alcohol Use Disorder

LOS ANGELES- The University of Calgary, through its Hotchkiss Brain Institute, has embarked on a study to examine the potential of psychedelics, specifically psilocybin, in treating Alcohol Use Disorder (AUD). With plans to recruit 128 participants, this research integrates specialized therapy sessions with psychedelic treatments to evaluate whether this novel approach can outperform conventional treatment methods.

Dr. Leah Mayo, leading the study, explains that the trial will build on the foundational benefits of psychotherapy for AUD, with psilocybin introduced to enhance treatment outcomes. This strategy aims to disrupt persistent negative behaviors by leveraging a brief but intensive treatment period, combining controlled psilocybin doses with psychotherapy over five weeks.

The study’s innovative therapy model, “motivational enhancement therapy,” focuses on fostering self-awareness and individualized change strategies, representing a shift from traditional, more confrontational treatment methods. Experts like Dr. David Hodgins highlight the transformative potential of this approach in AUD treatment.

Personal experiences shared by individuals such as John Greenwood and Jason Quilley emphasize the diversity of recovery paths and the critical role of therapy and community support in overcoming AUD. While opinions on the use of psychedelics in recovery vary, there’s a recognized value in therapeutic interventions and the power of supportive networks.

This research, supported by the Canadian Institutes in Health Research and Filament Health, which provides the psilocybin, could lead to more effective and compassionate treatment options for those battling alcohol use disorder.